ARMPHIGH SIGNALFINANCIAL10-K

ARMP experienced a catastrophic financial deterioration with net losses exploding from -$18.9M to -$173.8M (-818.8%) while stockholders' equity plummeted to -$218.6M, indicating severe financial distress.

The massive increase in net losses coupled with deeply negative stockholders' equity suggests the company is in severe financial distress and may face going concern issues. The dramatic jump in total liabilities from $134.5M to $295.5M alongside declining assets creates a precarious balance sheet structure that threatens the company's ability to continue operations without significant additional financing.

Comparing 2026-03-25 vs 2025-03-21View on EDGAR →
FINANCIAL ANALYSIS

ARMP's financial position deteriorated catastrophically with net losses increasing over 800% to -$173.8M while stockholders' equity collapsed to -$218.6M, creating a massive deficit. Total liabilities more than doubled to $295.5M even as total assets declined 11% to $76.9M, creating an unsustainable balance sheet structure. While operating cash flow improved modestly and current liabilities decreased significantly, these positive developments are overwhelmed by the massive losses and negative equity position, signaling potential bankruptcy risk without immediate capital infusion.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-818.8%
-$18.9M-$173.8M

Net income declined 818.8% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-355.2%
-$48.0M-$218.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+119.8%
$134.5M$295.5M

Liabilities grew 119.8% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
+100.8%
$4.9M$9.8M

R&D investment increased 100.8% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
-81.5%
$48.2M$8.9M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
-80%
$125K$25K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-71.2%
$1.9M$542K

Capex reduced 71.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+31.4%
-$37.6M-$25.8M

Operating cash flow surged 31.4% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+13.7%
-$42.4M-$36.6M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Assets
Balance Sheet
-11.1%
$86.4M$76.9M

Total assets contracted 11.1% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-21
ADDED
As of March 18, 2026, 36,632,775 shares of the Registrant s common stock were outstanding.
BUSINESS Overview We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered bacteriophages with our proprietary phage-specific host-engineered cGMP manufacturing capabilities to advance a clinical pipeline of high-quality bacteriophage product candidates.
We believe that we are uniquely advancing two distinct clinical candidates, referred to as AP-PA02 and AP-SA02, targeting two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection as well as acute systemic bacterial infection.
To date, we have completed three critical Phase 2 randomized, double-blind, placebo controlled clinical trials.
+7 more — sign up free →
REMOVED
As of February 28, 2025, 36,183,067 shares of the Registrant s common stock were outstanding.
This Annual Report includes trademarks and registered trademarks of Armata Pharmaceuticals, Inc.
BUSINESS Overview We are a clinical-stage biotechnology company having completed three Phase 2 trials focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
We have completed three critical Phase 2 trials, utilizing two distinct phage cocktails against two different bacterial pathogens with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection.
We believe we are on a critical pathway towards pivotal Phase 3 clinical studies.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →